OncoMatch

OncoMatch/Clinical Trials/NCT07015892

Dose-Escalation Radiotherapy in Limited-Stage Small Cell Lung Cancer: A Phase III Randomized Trial

Is NCT07015892 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies non-drug interventions for small cell lung carcinoma.

Phase 3RecruitingInstituto de Investigación Biomédica de SalamancaNCT07015892Data as of May 2026

This is a phase III clinical trial that aims to evaluate whether increasing the dose of radiotherapy given twice a day can improve treatment outcomes in patients with localized small cell lung cancer (SCLC). All patients will receive standard chemotherapy with cisplatin and etoposide and will be randomly assigned to one of three radiotherapy regimens. The main objective is to determine whether this intensified radiotherapy improves progression-free survival and overall survival. The study will also compare two different dose escalation strategies and assess treatment side effects and patients' quality of life. This research may help identify a more effective treatment approach for patients with limited-stage SCLC and could contribute to improving long-term survival in this aggressive type of cancer

Check if I qualify

Extracted eligibility criteria

Cancer type

Small Cell Lung Cancer

Disease stage

Required: Stage I, II, III

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

No prior treatment (treatment-naive required)
Max 0 prior lines

Cannot have received: thoracic radiotherapy

No prior thoracic radiotherapy

Cannot have received: surgery for any lung cancer

Prior surgery or radiotherapy for any lung cancer (SCLC or NSCLC)

Cannot have received: radiotherapy for any lung cancer

Prior surgery or radiotherapy for any lung cancer (SCLC or NSCLC)

Lab requirements

Blood counts

wbc ≥3.0×10⁹/l, neutrophils ≥1.5×10⁹/l, platelets ≥100×10⁹/l, hemoglobin ≥90 g/l

Kidney function

creatinine normal or crcl ≥60 ml/min

Liver function

total bilirubin ≤1.5×uln, ast/alt ≤1.5×uln

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify